Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study

Bin Ai, Li Zhang, Dingzhi Huang, Jun Chen, Zhe Liu, Xingsheng Hu, Shengyu Zhou, Yi Hu, Jun Zhao, Fan Yang, Bin Ai, Li Zhang, Dingzhi Huang, Jun Chen, Zhe Liu, Xingsheng Hu, Shengyu Zhou, Yi Hu, Jun Zhao, Fan Yang

Abstract

Bevacizumab is the first antiangiogenetic monoclonal antibody, combined with platinum-based double agent chemotherapy, which has been reported to improve the objective response rate (ORR) and progression-free survival (PFS) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC), and to improve overall survival (OS) in patients when combined with carboplatin and paclitaxel. However, serious adverse effects have been reported to be associated with bevacizumab therapy. In this multicenter prospective cohort study of advanced lung adenocarcinoma patients with stable disease after two cycles of platinum-based double agent chemotherapy, we will compare the ORR between the group who continued with their original chemotherapy regimen and the group in which bevacizumab was added to the original regimen. It is expected that there will be an ORR improvement of 20% in patients in the bevacizumab group plus chemotherapy, compared with those in the original chemotherapy group. This study has been registered as Clinical Trial NCT03240549.

Keywords: Bevacizumab; chemotherapy; lung adenocarcinoma.

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Figures

Figure 1
Figure 1
Reasearch process.

References

    1. Chen W, Zheng R, Baade PD et al Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–32.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
    1. Li X, Ai B, Zhang P, Li L, Wu X. Clinical research on albumin‐bound paclitaxel‐based therapy in advanced lung cancer. Zhongguo Fei Ai Za Zhi 2017; 20: 479–84.
    1. Shi YK, Wang L, Han BH et al First‐line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation‐positive lung adenocarcinoma (CONVINCE): A phase 3, open‐label, randomized study. Ann Oncol 2017; 28: 2443–50.
    1. Serritella AV, Bestvina CM. Anaplastic lymphoma kinase mutation‐positive non‐small cell lung cancer. Thorac Surg Clin 2020; 30: 137–46.
    1. Scagliotti GV, Parikh P, von Pawel J et al Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer. J Clin Oncol 2008; 26: 3543–51.
    1. Ciuleanu T, Brodowicz T, Zielinski C et al Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non‐small‐cell lung cancer: A randomised, double‐blind, phase 3 study. Lancet 2009; 374: 1432–40.
    1. Paz‐Ares L, de Marinis F, Dediu M et al Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non‐squamous non‐small‐cell lung cancer (PARAMOUNT): A double‐blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247–55.
    1. Ai B, Yang YF. Bevacizumab in the front‐line treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi 2020; 23: 626–30.
    1. Sandler A, Gray R, Perry MC et al Paclitaxel‐carboplatin alone or with bevacizumab for non‐small‐cell lung cancer. N Engl J Med 2006; 355 (24): 2542–50.
    1. Zhou C, Wu YL, Chen G et al BEYOND: A randomized, double‐blind, placebo‐controlled, multicenter, phase III study of first‐line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non‐small‐cell lung cancer. J Clin Oncol 2015; 33: 2197–204.
    1. Vergnenègre A, Tillon J, Corre R et al A randomized phase II trial assessing in advanced non‐small cell lung cancer patients with stable disease after two courses of cisplatin‐gemcitabine an early modification of chemotherapy doublet with paclitaxel‐gemcitabine versus continuation of cisplatin‐gemcitabine chemotherapy (GFPC 03‐01 study). J Thorac Oncol 2009; 4: 364–70.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅